About
CatalYm

The pioneer for GDF-15
targeting in immuno-oncology

CatalYm has identified GDF-15 as a key regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in nonresponsive tumors.

CatalYm’s lead program, CTL-002, is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.

Our Science

Our Pipeline

Latest News

Leadership Team

+
Managing Director and
Chief Executive Officer (CEO)
+
Chief Scientific Officer (CSO)
+
Chief Medical Officer (CMO)
+
Chief Financial Officer (CFO)

Board of Directors

John Haurum serves as the Chairman of the Board of Directors at CatalYm. In addition, John is a non-executive director of Agomab, Neophore, SynKlino and Storm. Previously, John served as CEO of F-star (...)

Read more
Board member

Andreas Wallnöfer is Partner at Jeito Capital and has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D (...)

Read more
Independent board member

Hans van Eenennaam most recently served as Chief Scientific Officer of AIMM Therapeutics and up until March 2019, as Executive Vice President of Antibody Research and Site Head for Aduro Biotech Europe. (...)

Read more
Board member

Jonathan Tobin prior to joining Brandon was a Managing Director at Arix Bioscience, a UK and US-based biotech venture firm. Prior to working at Arix, Jonathan spent five years at UK early-stage venture (...)

Read more
Board member

Marc Lohrmann is Managing Partner at Vesalius Biocapital III. He has over 20 years of experience and joined Vesalius Biocapital in 2012 as a venture partner and became a Managing Partner in 2017. Marc (...)

Read more
Board observer

Marianne Uteng is a Principal at the Novartis Venture Fund (NVF) in Basel, Switzerland. Prior to joining NVF, she worked at Novartis Global Drug Development and, before that, in the Pre-Clinical Safety (...)

Read more
Board observer

Nathalie Weitemeyer is senior investment manager at Bayern Kapital, the venture capital organisation of the Free State of Bavaria. She works on various projects in life science, computer science, engineering (...)

Read more
Board member

Oskar Slotboom joined BioGeneration Ventures as a partner in 2016, strengthening the team with his commercial, business development and consulting experience. Oskar started his career in McKinsey & (...)

Read more
Board member

Rogier Rooswinkel is Partner at Forbion where he is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. He currently serves (...)

Read more

Our Investors

Our mission is supported by a syndicate
of renowned life science investors

WordPress Cookie Notice by Real Cookie Banner